Drugs / BILB-1941
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02256787 | Jan → Sep 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02254707 | Jul 2004 → Apr 2006 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BILB-1941 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2181776 ↗ |
| Known as | BILB 1941 ZW | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02254707 ↗ |
| Modality | Small molecule | — CHEMBL2181776 ↗ |
| Route | Oral | “10 mg, 20 mg, 40 mg, 60 mg, 80 mg, 100 mg, 150 mg, 200 mg, 300 mg, 450 mg, 650 mg, 900 mg oral BILB 1941 ZW administered Q8H” NCT02254707 ↗ |